Histogen: Up on completing dosing for early-stage study of male baldness therapy

Histogen

05/10/2020 14:06

** Regenerative medicines maker's shares  HSTO.O  rise 5.1%
to $1.65 premarket
    ** Co reports completing patient dosing in an early-stage
clinical trial of HST-001, its candidate to treat androgenic
alopecia, or male pattern baldness, that causes early hair loss
in men 
    ** The early study was designed to assess safety,
tolerability and efficacy of HST-001 - co
    ** Co says it has completed dosing for week 12, the last of
three dosing timepoints, and is on track to announce topline
results in Q4 2020
    ** Says HST-001 has potential to stimulate new, long-lasting
hair growth in contrast to the two FDA approved therapies that
focus on reducing hair loss    
    ** Up to last close, HSTO stock down ~60% YTD

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))